Descripción del proyecto
Una vacuna contra el cáncer disponible en el mercado
Aprovechar el sistema inmunitario para luchar contra el cáncer es un concepto prometedor, pero hasta ahora el éxito clínico ha sido limitado. La razón subyacente es la presencia de células madre cancerosas (CMC) que que ofrecen resistencia y causan recidivas del tumor. El equipo del proyecto MUTAVAC, financiado por el Consejo Europeo de Innovación, propone generar una versión altamente inmunogénica de IPVAC, una inmunoterapia basada en células madre pluripotentes inducidas generadas con los antígenos de las CMC. Esta terapia celular tiene el potencial de servir tanto en la prevención como en la terapia de cánceres con características de CMC. Es más, esta terapia celular puede ampliarse para su uso clínico y, a su vez, personalizarse para adaptarse a las características exclusivas de cada tumor.
Objetivo
The successful application of immune checkpoints inhibitors has modified the therapeutic strategies in several cancers but only 30% of patients will respond optimally to these therapies. One of the reasons for the failure of these therapies is the resistance of cancer stem cells (CSCs) leading to relapses long after the initial treatment. These cells are also resistant to conventional therapies via their quiescence and there are no targeted therapies available against them. The ambition of IPSIRIUS, a French biotechnology company, spinoff of INSERM and Paris Saclay University is to develop active cancer immunotherapy products based on the revolutionary induced pluripotent stem cell (iPSC) technology. IPSIRIUS developed first IPVAC, with the aim of leveraging patient’s immune system against a large panel of cancer antigens which are shared between iPSC and CSCs. With IPVAC, IPSIRIUS is developing a ground-breaking technology, having resolved all technical issues limiting cell-based therapies used for cancer. IPVAC is a safe, allogenic, off-the-shelf therapy, highly scalable using a versatile technology. This cell-based vaccination strategy showed efficacy in prophylactic and therapeutic settings against aggressive solid cancers with stemness features. The overall goal of the MUTAVAC project is i) to uncover the mechanisms of action of IPVAC, ii) to generate a highly immunogenic version of IPVAC, and iii) to design robust in vitro immunogenicity tests to predict immunogenicity of IPVAC and IPVAC-Mut in humans. With MUTAVAC project, IPSIRIUS will i) strengthen the scientific data on IPVAC to prepare its clinical development and leading to the open access publications and patents, ii) define a personalised medicine to propose efficient therapeutic cancer vaccine in patients with all HLA groups, iii) identify new targets for future cancer therapies, and iv) develop a technological platform to facilitate the development of the next-generation of cell therapies.
Ámbito científico
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Tema(s)
Convocatoria de propuestas
HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinador
75005 PARIS
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.